Fundamental XR expands access to immersive training with web-enabled platform

Tern plc

Fundamental XR has launched Immersive Web, a platform designed to extend immersive training beyond headset-only environments and into the browser.

The company’s core proposition has centred on delivering high-fidelity, hands-on training through virtual environments. While immersive hardware enables realistic and repeatable skill development, full deployment can require logistical planning, capital investment and on-site coordination. Immersive Web introduces a browser-based layer that allows elements of training to be accessed without dedicated equipment, widening the potential user base and reducing friction at the point of entry.

This approach alters the economics of implementation. Organisations can begin engagement through standard web browsers, enabling learners to complete preparatory modules, theoretical instruction and guided walkthroughs before progressing to fully immersive simulations. By separating foundational learning from advanced practical application, the platform supports a more staged investment model.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Tern plc raises £450,000 in share placing ahead of AIM admission

Tern plc has raised £450,000 through a placing and outlined expected admission timing and updated voting rights.

Search